Australian researchers stopping melanoma in its tracks

Australian researchers stopping melanoma in its tracks

11 September 2017

A team of Australian researchers has made the ultimate move in the battle to beat melanoma, successfully trialling a combination of new treatments to stop the disease in its tracks and prevent it from spreading or metastasising to distant organs.

Melanoma is the deadliest form of skin cancer, with one Australian dying from advanced melanoma every five hours.

Ground-breaking results from two international clinical trials conducted by investigators at Melanoma Institute Australia are being presented today at one of the world’s largest medical oncology conferences, the European Society for Medical Oncology (ESMO) 2017 Congress in Spain. The research has also been published in the prestigious New England Journal of Medicine today.

The trials, COMBI-AD and CheckMate 238, proved successful in preventing the spread of disease in Stage III melanoma patients whose tumours had been surgically removed. Until now, these patients were at a high risk (40−70 per cent) of their disease progressing to advanced and fatal melanoma.

“These results will change the way we treat melanoma patients as well as their quality of life,” says study author Professor Georgina Long (pictured), Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney. 

“Until now, Stage III melanoma patients who have had their tumours surgically removed have simply had to play the waiting game, to see if their melanoma would metastasise or spread. Living with such fear severely affected them and their loved ones.

“Results from these clinical trials suggest we can stop the disease in its tracks – effectively preventing it from spreading and saving lives. Our ultimate goal of making melanoma a chronic rather than a terminal illness is now so much closer to being achieved,” she said.

In the COMBI-AD trial, patients were randomised to receive a combination of targeted therapies (dabrafenib and trametinib) or placebo for 12 months. Targeted therapies block the action of a particular gene which is a driver for melanoma. It was aimed at patients who are BRAF positive. It not only prevented resected Stage III melanoma from recurring, but it increased overall survival.

The CheckMate 238 trial involved patients with high risk Stage III and Stage IV disease who had had all melanoma surgically removed. They were randomised to be treated with the immunotherapy nivolumab or ipilimumab for 12 months.  Immunotherapies reboot the immune system to attack the melanoma cells. Results showed nivolumab decreased the chance of relapse, and it had a superior safety profile over ipilimumab. This benefit was seen in patients regardless of BRAF mutation status. The follow up period is too short to yet determine long-term survival rates.

Research had already shown that targeted and immune therapies can successfully treat patients with advanced (Stage IV) melanoma that could not be removed surgically.

These clinical trials are the first in the world to give the treatments to melanoma patients at an earlier stage of the disease to prevent spread and recurrence.

“These clinical trials show we now have ammunition to prevent melanoma spreading and progressing, which until now was a critical area of disease behaviour where we had no control,” Professor Long said.

“This will change how melanoma is treated around the world, as we no longer have to passively wait to see if the melanoma spreads.

“We can now actively and effectively attack the melanoma at an earlier stage, reducing the dreadful anxiety for patients about progressing to a potentially terminal illness and ensuring they have much better outcomes,” she said.  

History teacher and mother Renae Aslanis was a patient on the COMBI-AD trial. After having 10 lymph nodes removed, she decided to enter the clinical trial rather than just "watching and waiting". Now four-and-a-half years later, she is still "going strong"! Read more.

Download the media release

Renae

Publications:

A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma
Professor Georgina Long hands on baton of SMR Presidency
31 Oct 2020

Professor Georgina Long hands on baton of SMR Presidency

Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

Tags: melanoma
City2Surf 2020
11 Sep 2020

City2Surf 2020

Join in the fun of the virtual event, and together we can run over melanoma!

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts at MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts from MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Melanoma Supportive Care Needs research study. 
03 Sep 2020

Melanoma Supportive Care Needs research study. 

Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New online melanoma risk calculators critical to saving lives
28 Aug 2020

New online melanoma risk calculators critical to saving lives

Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Tags: melanoma
Professor Richard Scolyer receives University of Sydney Alumni Award.
24 Aug 2020

Professor Richard Scolyer receives University of Sydney Alumni Award.

MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Tags: melanoma
Uniting together despite the distance
21 Aug 2020

Uniting together despite the distance

More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Tags: melanoma
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
03 Aug 2020

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.

For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Tags: melanoma
Important Update: Masks required at Poche Centre
24 Jul 2020

Important Update: Masks required at Poche Centre

As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask. 

Tags: melanoma